The microbiome therapeutics market is expected to reach USD 433.5 million by 2025, based on a new study by Grand View Research, Inc. Increasing funding initiatives and government programs to support this research are high impact rendering drivers anticipated to foster market growth.
Browse the report: http://www.orbisresearch.com/reports/index/microbiome-therapeutics-market-by-type-fecal-microbial-transplant-fmt-drugs-by-application-c-difficile-crohns-disease-inflammatory-bowel-disease-ibd-diabetes-by-region-and-segment-forecasts-2014-2025
The launch of Human Microbiome Project by NHS in Europe and the Microbiome Initiative by the U.S. government are some of the crucial government initiatives pertaining to market growth. The U.S. government has announced to have invested over USD 121 million in the Microbiome Initiative with additional USD 100 million from the Bill and Melinda Gates Foundation.
Presence of strong drug pipeline can also be attributed to the highly lucrative growth. Key players are entering into collaborative agreements with venture capital firms and research institutes for enhancing therapeutics pipeline through development of efficient and safe drugs. Some of the companies that recently formed collaborative agreements are Seventure Partners & ENTEROME Bioscience; Vedanta Biosciences & Johnson & Johnson Pvt. Ltd.; and Seventure Partners & Eligo Bioscience.
Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/200914
Further Key Findings from the Study Suggest:
Fecal Microbial Transplant (FMT) held the largest market share in 2015 owing to easier availability and introduction of FMT capsules by Open Biome
Introduction of RBX2660, a phase 3 molecule, during the end of 2018 will result in substantial increase in revenue of FMT
No commercial microbiome drugs are currently available with FMT being the only therapy for treatment. Drugs are estimated to hit the market by fourth quarter of 2017.
It is estimated that the drugs segment would witness the fastest growth owing to the presence of blockbuster drugs, such as, NM504, SER-109, RP-G28, and SGM-1019, in the pipeline.
Buy the report@http://www.orbisresearch.com/contact/purchase/200914
C. difficile dominated the application segment in 2015 with Crohn’s disease leading the market CAGR over the forecast period.
North America held the largest share in 2015, owing to presence of major companies & established healthcare infrastructure and high amount of research activities.
Asia Pacific is anticipated to witness significant growth with increasing acceptance of FMT in developing countries, such as India and China.
Some of the key companies are MicroBiome Therapeutics, LLC; Seres Therapeutics; ENTEROME Bioscience; MaaT Pharma; Rebiotix, Inc.; Ritter Pharmaceuticals; Second Genome, Inc.; and OpenBiome.
High investment on research and development of new drugs and investigation of available drugs for more untapped applications are the main strategies undertaken by the key players.
Major Points From Table Of Contents:
Chapter One: Research Methodology & Scope
Chapter Two: Executive Summary
Chapter Three: Microbiome Market Variables, Trends & Scope
Chapter Four: Microbiome Market: Type Estimates & Trend Analysis
Chapter Five: Microbiome Market: Application Estimates & Trend Analysis
Chapter Six: Microbiome Market: Regional Estimates & Trend Analysis, by Application
Chapter Seven: Competitive Landscape
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019